Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.58 |
| ▸ | BTK | Q06187 | 4/20 | 0.56 |
| ▸ | RET | P07949 | 2/20 | 0.56 |
| ▸ | FYN | P06241 | 7/20 | 0.52 |
| ▸ | SRC | P12931 | 6/20 | 0.52 |
| ▸ | ABL1 | P00519 | 4/20 | 0.52 |
| ▸ | YES1 | P07947 | 3/20 | 0.52 |
| ▸ | LYN | P07948 | 3/20 | 0.52 |
| ▸ | BLK | P51451 | 3/20 | 0.52 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23997157 | 0.90 | CYP1A2 (0.83) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL24096507 | 0.85 | CYP1A2 (0.59) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL29781037 | 0.85 | CYP1A2 (0.64) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL29998849 | 0.84 | PRKD3 (0.58) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL24096616 | 0.84 | PRKD3 (0.58) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL29781148 | 0.81 | SRC (0.59) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL29780889 | 0.81 | SRC (0.64) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL29052195 | 0.81 | SRC (0.59) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL17962837 | 0.81 | SRC (0.71) | PRKD3SRCABL1EGFRKDR | |
| SCHEMBL13019782 | 0.80 | CYP1A2 (1.00) | CYP1A2KDM4EMAPK1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| CN-116075513-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-4161933-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2021252488-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | CYP1A2 3396/4885KDM4E 1783/4885MAPK1 228/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | CYP1A2 4720/4885KDM4E 4052/4885MAPK1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.